ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting

    Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis

    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
  • Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting

    Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Masataka Kuwana2, Ning Li3, Julio Charles4, Faye N. Hant5, Galina S. Bogatkevich6, Tanjina Akter6, Michael Roth7, Hyun J. Grace Kim8, Jonathan Goldin9, Dinesh Khanna10, Philip J. Clements11, Daniel E. Furst7, Robert Elashoff12, Rick Silver13 and Shervin Assassi14, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 3Biomathematics, University of California, Los Angeles, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Rheumatology, Medical University of South Carolina, Charleston, SC, 6Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 7Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 8Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, 9Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, 10Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 11Medicine, University of California, Los Angeles, Los Angeles, CA, 12University of California, Los Angeles, Los Angeles, CA, 13Rheumatology, Medical University of SC, Charleston, SC, 14University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
  • Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting

    Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies

    Sara Sabbagh1, Iago Pinal-Fernandez1, Takayuki Kishi2, Ira N. Targoff3, Frederick W. Miller2, Lisa G. Rider2 and Andrew Mammen1,4, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Environmental Health Sciences, National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, 3VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…
  • Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting

    Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Myung Sim1, Ning Li2, Dinesh Khanna3, Michael Roth4, Philip J. Clements4, Anna-Maria Hoffmann-Vold5, Daniel E. Furst1, Grace Kim6, Jonathan Goldin1 and Robert Elashoff7, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Biomathematics, University of California, Los Angeles, Los Angeles, CA, 3University of Michigan, Ann Arbor, MI, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5Oslo University Hospital, Oslo, Norway, 6Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 7University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
  • Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting

    Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014

    Osman Bhatty1, Rouhin Sen1, Douglas Moore2 and Joseph Nahas3, 1Department of Medicine, CHI Creighton University Medical Center, Omaha, NE, 2Department of Pulmonary/Critical Care, CHI Creighton University Medical Center, Omaha, NE, 3Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…
  • Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting

    CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice

    Sho Sendo1, Jun Saegusa1, Hirotaka Yamada2, Yoshihide Ichise2, Ikuko Naka3, Yo Ueda2, Takaichi Okano2, Soshi Takahashi4, Kengo Akashi5, Akira Onishi6 and Akio Morinobu4, 1Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 4Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

    CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
  • Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting

    The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts

    Elizabeth R. Volkmann1, Donald P. Tashkin1, Myung Sim1, Dinesh Khanna2, Michael Roth3, Philip J. Clements3, Daniel E. Furst1, Lynette Keyes-Elstein4, Ashley Pinckney4, Ellen Goldmuntz5, Robert Elashoff6 and Keith Sullivan7, 1University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2University of Michigan, Ann Arbor, MI, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Rho Federal Systems, Inc., Chapel Hill, NC, 5NIAID, NIH, Bethesda, MD, 6University of California, Los Angeles, Los Angeles, CA, 7Duke University, Durham, NC

    Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
  • Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting

    Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration

    Richard Bell1, Emily Wu1,2, Homaira Rahimi3 and Edward Schwarz1,4,5, 1Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 2Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 3Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, 4University of Rochester, Rochester, NY, 5Univ of Rochester Med Ctr, University of Rochester School of Medicine and Dentistry, Rochester, NY

    Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…
  • Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting

    Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease

    Yuki Ichimura, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Tomoaki Higuchi, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…
  • Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting

    Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease

    Robert L. Mango1, Eric L. Matteson2, Cynthia S. Crowson3, Jay H. Ryu4 and Ashima Makol2, 1Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN

    Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…
  • Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting

    Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore

    Maria Noviani1, Seyed Ehsan Saffari2, Sandra Mei Yu Kua1, Grace Yin Lai Chan3, Gim Gee Teng4, Weng Giap Law5, Amelia Santosa4, Anita Yee Nah Lim4, Swee Cheng Ng1 and Andrea Hsiu Ling Low1, 1Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, 2Center for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore, Singapore, 3Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, SIngapore, Singapore, 4Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, Singapore, 5Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore, Singapore

    Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc).  We aimed to determine…
  • Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting

    “Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”

    Diego Baenas1, Maira Orozco2, María Eugenia Olmos3, Luis Lasca4, Paula Riba5, Patricio Muszinsky5, Juan Pablo Pirola6, Verónica Saurit7, Alejandro Alvarellos7, Ana C. Alvarez8, Soledad Retamozo9,10, Nadia Riscanevo7,11, Janet Flores12, Ariel Blua3, Ana María López13, Gustavo Muiño14, Santiago Orozco15 and Francisco Caeiro16, 1Rheumatology Unit, Hospital Privado Universitario de Córdoba, Postgraduate Career of Rheumatology Catholic University of Córdoba., Cordoba, Argentina, 2Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 3Pulmonary, Pulmonary Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 4Radiology Unit, Oulton Institute, Cordoba, Argentina, 5Radiology, Radiology Unit, Oulton Institute, Cordoba, Argentina, 6Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 7Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 8Rheumatology, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, 9Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, 10Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 11Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 12Rheumatology Unit, Rheumatology Unit, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 13Pulmonary Unit, Pulmonary Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 14Radiology, Radiology Unit,Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 15Radiology, Radiology Unit, Hospital Privado Universitario de Córdoba., Cordoba, Argentina, 16Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina

    Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…
  • Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting

    Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?

    Sepehr Mesdaghinia1, Julio Arturo Huapaya2, Brainerd Ewarien2 and Virginia D. Steen1, 1Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 2Medicine, MedStar Georgetown University Hospital, Washington, DC

    -       Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD).  It is important to separate these patients…
  • Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting

    Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

    Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
  • Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting

    The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

    Yumiko Sugiyama1,2, Ryusuke Yoshimi1,2, Maasa Tamura2,3, Naoki Hamada1,2, Hideto Nagai1,2, Naomi Tsuchida1,4, Yosuke Kunishita1,2, Yutaro Soejima1,2, Daiga Kishimoto1,2, Reikou Kamiyama1,2, Kaoru Minegishi1,5, Yohei Kirino1,2, Shigeru Ohno1,6 and Hideaki Nakajima2, 1Y-CURD Study Group, Yokohama, Japan, 2Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 3Y-CURD Study Group, Yokohma, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, 6Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan

    Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies